Fortrea Holdings Inc. ((FTRE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fortrea Holdings Inc. (FTRE) is involved in a Phase 1 study titled A Phase 1, Single-Center, Open-Label, Single-Arm, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety and Tolerability, Immunogenicity, Pharmacokinetics, Dosimetry and Biodistribution Following GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers. The study aims to evaluate the safety and tolerability of the investigational medicinal products (IMPs), with a focus on the pharmacokinetics and biodistribution of GEH200521 (18F) Injection when used alongside GEH200520 Injection.
The interventions being tested include the GEH200520 Injection and GEH200521 (18F) Injection, which are administered together. The purpose of these interventions is to assess their safety and distribution in the body using positron emission tomography (PET) scans.
This study is designed as a single-center, open-label, single-arm, dose-escalation trial. It involves non-randomized allocation and follows a sequential intervention model. There is no masking involved, and the primary purpose is diagnostic, focusing on safety and biodistribution.
The study began on April 23, 2024, with the last update submitted on June 17, 2025. These dates are crucial as they indicate the study’s progress and the timeliness of the data being collected.
The market implications of this study are significant for Fortrea Holdings Inc. and its collaborators, GE Healthcare and PPD Development, LP. Positive outcomes could enhance investor confidence and potentially boost stock performance. The study’s progress may also influence the competitive landscape in the diagnostic imaging industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.